InstalabLoading...
InstalabLoading...
A steroid metabolite of the body's most potent androgen that reflects how actively your tissues are processing testosterone and signals androgenic activity in skin, prostate, and the nervous system.
When your body breaks down testosterone, it does not simply discard the pieces. One of those pieces, 5α-androstanediol (5α-androstane-3α,17β-diol), turns out to carry real biological weight. Measuring it, usually in the form of its tagged version called a glucuronide, gives you a window into how aggressively your tissues are converting testosterone into its most powerful form, dihydrotestosterone (DHT), and what happens to DHT after it does its work. If your level is elevated, it suggests your body's androgen processing machinery is running hot, which has implications for hair growth patterns, prostate health, and hormonal balance.
This is not a first-line screening test. It is a second-layer tool, most useful when you already suspect something is off with your androgen metabolism and want a more specific answer than testosterone or DHT alone can give you. For women dealing with excess hair growth in male-pattern areas, it can reveal hidden androgen overactivity that standard blood tests miss. For men, it connects to prostate biology in ways that matter both for cancer surveillance and for understanding how your body responds to hormonal therapies.
5α-androstanediol is a breakdown product of DHT, which is itself made from testosterone. The classic sequence runs like this: testosterone is converted to DHT by an enzyme called 5α-reductase, and then DHT is converted to 5α-androstanediol by another enzyme family called 3α-hydroxysteroid dehydrogenases. This happens primarily in your liver, prostate, and other tissues that are responsive to androgens.
Here is what makes this molecule more interesting than a simple waste product: the conversion is reversible. Your body can turn 5α-androstanediol back into DHT when it needs to. This two-way street means that 5α-androstanediol is not just evidence that DHT was broken down. It is also a reservoir that tissues can draw from to regenerate DHT locally, even when overall androgen levels are low.
There is also a so-called "backdoor" pathway. Instead of following the standard testosterone-to-DHT-to-androstanediol route, some tissues (including the testes) can produce 5α-androstanediol directly and then convert it to DHT in peripheral tissues. This alternate route plays an important role in normal male development and in certain hormonal conditions like congenital adrenal hyperplasia and polycystic ovarian syndrome (PCOS).
The most established clinical use of this biomarker is measuring its glucuronide form in the blood as a marker of how much DHT activity is happening in your peripheral tissues, particularly your skin and prostate. Standard testosterone blood tests tell you what is circulating. 5α-androstanediol glucuronide tells you what is happening at the tissue level, where androgens actually do their work.
Urinary excretion of 5α-androstanediol is significantly higher in men than in women: roughly 193 micrograms per 24 hours in men compared with about 44 micrograms per 24 hours in women. Women with hirsutism (excess hair growth in a male pattern) show elevated levels, which helps confirm that the hair growth is driven by androgen overactivity rather than something else.
If you are a woman and your level is elevated, it signals that your tissues are converting androgens more aggressively than expected, even if your circulating testosterone looks normal. This is especially relevant in evaluating conditions like PCOS or unexplained hirsutism, where the problem may not be how much testosterone you are producing but how vigorously your tissues are using it.
5α-androstanediol does not only reflect androgen metabolism. It has its own biological effects that operate through at least three different pathways, depending on which form of the molecule is involved.
The first is a brain-calming effect. The 3α form of 5α-androstanediol acts on GABA-A receptors, the same receptors targeted by drugs like benzodiazepines and alcohol. By enhancing the activity of GABA, the brain's primary inhibitory chemical messenger, it has anticonvulsant properties and may modulate mood. This is part of why testosterone's effects on the nervous system are more complex than simple "androgen signaling." Some of testosterone's downstream metabolites are actually functioning as neurosteroids, calming neural circuits rather than stimulating them.
The second involves a hormone-like action in the prostate. 5α-androstanediol stimulates a cellular signaling molecule called cAMP in prostate tissue through a specific receptor system, at concentrations that naturally occur in male blood. This means it is not just a passive metabolite; it is actively communicating with prostate cells.
The third is an estrogen-like protective effect. The 3β form of 5α-androstanediol activates estrogen receptor beta (ERβ), a receptor associated with anti-growth and anti-migration signals in prostate cancer cells. Through this pathway, it can inhibit cancer cell migration and promote cellular adhesion, suggesting a potential protective role against metastasis. This is a surprising finding: a testosterone derivative acting through an estrogen receptor to restrain cancer spread.
For men undergoing treatment for advanced prostate cancer, 5α-androstanediol has a very specific and important role. In castration-resistant prostate cancer, where the disease progresses despite therapies that suppress circulating testosterone, tumors have been shown to convert 5α-androstanediol back into DHT through the enzyme 17β-hydroxysteroid dehydrogenase 6. This backdoor route for regenerating DHT inside the tumor itself is one reason prostate cancer can continue growing even when systemic androgen levels are very low.
This intratumoral conversion represents a potential therapeutic target. Drugs that block this specific backdoor pathway could enhance the effectiveness of standard androgen deprivation therapy, including LHRH agonists, androgen receptor blockers, and 5α-reductase inhibitors. If you are managing advanced prostate cancer, this is a conversation worth having with your oncologist.
There is also evidence that 5α-androstanediol can promote prostate cancer progression through an entirely different mechanism: by activating GABA-A receptors on cancer cells, independent of the androgen receptor. This means the molecule may have a dual nature in prostate cancer biology, with one form (3β) restraining cancer through estrogen receptor beta, and the neurosteroid pathway potentially promoting progression.